Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lin-Ping Shi"'
Autor:
Lin-Ping Shi, Wen-Liang Li, Pu-Yue Wang, Xiao-Ming Wu, Zhao-Quan Yao, Jiong-Peng Zhao, Fu-Chen Liu
Publikováno v:
Inorganic Chemistry Frontiers; 6/7/2024, Vol. 11 Issue 11, p3309-3315, 7p
Autor:
Li-Min Zhu, Wen-Liang Li, Tian-Ran Li, Lin-Ping Shi, Li-Ting Li, Zhao-Quan Yao, Hong-Liang Huang, Jiong-Peng Zhao, Fu-Chen Liu
Publikováno v:
Inorganic Chemistry Frontiers. 10:2438-2443
A pillar-layered dense 3d–4f MOF shows high IAST selectivity for CH4/N2 owing to the enhancement of the interactions between the MOF and CH4 by the heteroatoms of the pillars.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c5f5b569002f02bc12deb008b2c41cb1
https://doi.org/10.1039/d3qi00235g
https://doi.org/10.1039/d3qi00235g
Autor:
Xiaoyu Jiang, Shuling Wang, Yijun Wang, Lin-Ping Shi, Shengbin Qi, Huiqing Jiang, Shiying Dou, Sheng-Xiong Chen, Ruo-Lin Cui, Ting Liu, Jiu-Na Zhang, Hongqun Liu, Shu-Jia Chen, Yongjuan Wang, Xiao-Li Xie, Xue Zhou
Publikováno v:
Journal of Cellular and Molecular Medicine
Triggering receptor expressed on myeloid cells‐1 (TREM‐1) exists in two forms: a transmembrane form and a soluble form (sTREM‐1). The levels of sTREM‐1 are elevated in supernatants of activated HSCs. However, the role of sTREM‐1 in HSC acti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::007933606905265a7685b1c75807d545
https://doi.org/10.1111/jcmm.17033
https://doi.org/10.1111/jcmm.17033
Autor:
Jiu-Na Zhang, Yongjuan Wang, Ting Liu, Lin-Ping Shi, Xiaoyu Jiang, Xiao-Li Xie, Yijun Wang, Huiqing Jiang, Shu-Jia Chen, Shiying Dou, Ruo-Lin Cui, Xue Zhou, Sheng-Xiong Chen, Shuling Wang
Publikováno v:
World Journal of Gastroenterology. 27:4667-4686
Background Sorafenib is the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Y-box binding protein 1 (YB-1) is closely correlated with tumors and drug resistance. However, the relationship between YB-1 and sorafenib res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5453ead19ebcc0e69e6fb70ef8958eb0
https://doi.org/10.3748/wjg.v27.i28.4667
https://doi.org/10.3748/wjg.v27.i28.4667
Autor:
Ting, Liu, Xiao-Li, Xie, Xue, Zhou, Sheng-Xiong, Chen, Yi-Jun, Wang, Lin-Ping, Shi, Shu-Jia, Chen, Yong-Juan, Wang, Shu-Ling, Wang, Jiu-Na, Zhang, Shi-Ying, Dou, Xiao-Yu, Jiang, Ruo-Lin, Cui, Hui-Qing, Jiang
Publikováno v:
World Journal of Gastroenterology
BACKGROUND Sorafenib is the first-line treatment for patients with advanced hepatocellular carcinoma (HCC). Y-box binding protein 1 (YB-1) is closely correlated with tumors and drug resistance. However, the relationship between YB-1 and sorafenib res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5d853251617a2357145d8b3580012b37
https://pubmed.ncbi.nlm.nih.gov/34366628
https://pubmed.ncbi.nlm.nih.gov/34366628